Amgen Inc 

AMGN:NASDAQ

LastChange / % ChangeDividend YieldVolume
56.50 0.1800   0.32%0.00%5,893,725

Market data is delayed by at least 20 minutes.

Exclusive Features

When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes.

For full analysis details, Log In with Scottrade or you can:
  •  
    Advanced Charts

  •  
    Embed Chart

    Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

  • 1 Day
  • 5 Day
  • 6 Mo
  • 1 Yr
  • 5 Yr
 
 
 

Latest News Headlines for Amgen Inc

Amgen Set to Possibly Pullback after Yesterday's Rally of 0.32% (AMGN)
19 hours 36 minutes ago - Comtex SmarTrend(R)
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $56.05 to a high of $57.28. Yesterday, the shares gained 0.32%, which took the trading range above the 3-day high of $57.00 on volume of 5.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Upside Reversal for Amgen
3 days 7 hours 11 minutes ago - Advicetrade
Upside Reversal for Amgen By Mike Paulenoff, www.MPTrader.com an AdviceTrade.com publication Today's sharp morning session upside reversal in Amgen (AMGN) is "threatening" to put in a key upside reversal day -- provided the stock closes above 57.14. So far today, the action has the right look and feel of a price structure that ended a correction -- in this case a sideways digestion period since Jan 4 -- ahead of a thrust into a new upleg.
Through 1278 SPX....
5 days 2 hours 36 minutes ago - Advicetrade
by Jack Steiman, www.SwingTradeOnline.com an AdviceTrade.com publication The market has been gravitating higher slowly but surely, no question. Over the past many weeks it had set up shop between the gap top low at 1262 and the 1278 as its high. A few tests down at 1262 looked like a breakdown was finally upon us, but that was not to be. There were many test back up to 1278, but failed as well, so it became a chess match between who would make the move first. The bulls pulled off the move today. It wasn't a shocking move higher as we're barely above 1278. Slightly less than half a percent above, but we are above, and that can't be denied by anyone. This opens the door to a move up to the top of the trend line at 1300 on the S&P; 500. That chart is there for your viewing this evening. It seems as if this market doesn't waste a point. Although, by no means a guarantee, if the trend line is open to approximately 1300 on the SPX, it seems as if it will find a way to make it there, even if it doesn't hold once it does get there.
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
March 1, 2010
This report contains detailed information about the company's business finances and management.
10-Q
November 8, 2010
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Amgen Inc. (Amgen) is an independent biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. Its principal products include Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body's response to inflammatory diseases.
Bid/Size
-- / --
Ask/Size
-- / --
Price Open
56.05
Previous Close
56.32
Day High
57.28
Day Low
56.05
52wk High/Date
61.26 / 4/19/2010
52wk Low/Date
50.26 / 8/27/2010
Beta
0.47
Market Capitalization
53B
Shares Outstanding
945M
Volatility Avg
22.50
Avg Vol(10 day)
5M
P/E Ratio
12.2x
EPS (TTM)
5
Annualized Rate
-- / --
Yield
0.00%
Dividend Announcement
--
Ex-Date
--
Date of Record
--
Payable
0.00 - --
Payable Date
--
Last Trade as of 1/14/2011 4:00 PM ET

Exclusive Content

When you open an account with Scottrade, you will get premium content on the News & Content page, including:

  • Standard & Poor's News and Commentary
  • Dow Jones News
  • Briefing News and Commentary
  • Market Edge On the Edge Commentary
For full analysis details, Log In with Scottrade or you can:
 
 
 

AMGN Amgen Inc vs. Peers

Peers 
AMGN
Amgen Inc
2.91%
JNJ
Johnson & Johnson
1.13%
HSP
Hospira, Inc.
1.08%
MRK
Merck & Co., Inc.
-5.02%
ABT
Abbott Laboratories
-2.13%
AMGN
Amgen Inc
0.00%
JNJ
Johnson & Johnson
3.45%
HSP
Hospira, Inc.
--
MRK
Merck & Co., Inc.
4.44%
ABT
Abbott Laboratories
3.75%
AMGN
Amgen Inc
0.32%
JNJ
Johnson & Johnson
-0.57%
HSP
Hospira, Inc.
0.16%
MRK
Merck & Co., Inc.
-1.33%
ABT
Abbott Laboratories
-1.01%
Compare these stocks
 
 
 
© 2011 Scottrade

Brokerage Products and Services offered by Scottrade, Inc. - Member FINRA and SIPC

Online market and limit stock trades are just $7 for stocks priced $1 and above.

Any specific securities, or types of securities, used as examples are for demonstration purposes only. No information on this Web site should be considered a recommendation or None of the information provided should be considered a recommendation or solicitation to invest in, or liquidate, a particular security or type of security.

Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund carefully before investing. A mutual fund's prospectus contains this and other information about the mutual fund. Prospectuses are available through our trading site or through a Scottrade Branch Office. The prospectus should be read carefully before investing. No transaction fee (NTF) funds are subject to the terms and conditions of the NTF funds program. Scottrade is compensated by the funds participating in the NTF program through recordkeeping, shareholder, or SEC 12b-1 fees.

Investors should consider the investment objectives, charges, expense, and unique risk profile of an Exchange Traded Fund (ETF) carefully before investing. Leveraged and Inverse ETFs may not be suitable for long-term investors and may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies. A prospectus contains this and other information about the ETF and should be obtained from the issuer. The prospectus should be read carefully before investing.

Margin trading involves interest charges and risks, including the potential to lose more than deposited, or the need to deposit additional collateral in a falling market. Margin Disclosure Statement (PDF) is available for download, or it is available at one of our branch offices. It contains information on our lending policies, interest charges, and the risks associated with margin accounts.

Options involve risk and are not suitable for all investors. Detailed information on our policies and the risks associated with options can be found in the Scottrade Options Application and Agreement, Brokerage Account Agreement, and by downloading the Characteristics and Risks of Standardized Options and Supplements (PDF) from The Options Clearing Corporation, or by requesting a copy from your local branch office. Supporting documentation for any claims will be supplied upon request.

Market volatility, volume, and system availability may impact account access and trade execution.

Testimonials may not be representative of the experience of other clients and are no guarantee of future performance or success.